VBI Vaccines Inc. - Special Call Transcript
Good morning, and thank you all for joining us on the call today. I'm Jeff Baxter, CEO of VBI, and I'm very excited to share with you this initial positive and encouraging interim Phase Ib/IIa data from VBI-2601, our immunotherapeutic candidate for the treatment of chronic hepatitis B infection.
This study has been conducted by our partner, Brii Biosciences, at clinical sites in New Zealand, Australia, Thailand, South Korea, Hong Kong and China.
A brief word on Brii. In these unprecedented pandemic times, Brii has been an exemplary partner who have executed flawlessly this study against an incredibly difficult backdrop. I would like to recognize our achievement and express our thanks.
This is the first interim readout from this study, and these early data from the low dose cohorts are very encouraging, providing us with a human proof-of-concept that leads us to believe the VBI-2601, BRII-179 could be an effective and critical component of a functional cure for chronic hepatitis B. Here with me to discuss the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
